상세 가이드 곧 제공 예정
Glucose Infusion Rate (GIR)에 대한 종합 교육 가이드를 준비 중입니다. 단계별 설명, 공식, 실제 예제 및 전문가 팁을 곧 확인하세요.
The Glucose Infusion Rate (GIR) is a measure of the rate at which glucose is delivered to a patient via intravenous infusion, expressed in milligrams of glucose per kilogram of body weight per minute (mg/kg/min). It is a fundamental parameter in neonatal and paediatric intensive care medicine, where intravenous glucose provision must be precisely calibrated to match the metabolic glucose requirement without causing hyperglycaemia or hypoglycaemia. In neonates, the brain depends almost entirely on glucose as its fuel source, and hypoglycaemia in the neonatal period can cause permanent neurological injury. The normal hepatic glucose production rate in term neonates is approximately 4-6 mg/kg/min, which defines the lower end of the target GIR range. Premature neonates may have higher glucose requirements due to reduced hepatic glycogen stores and relatively larger brain-to-body mass ratios. The upper recommended GIR for most neonates is 8-10 mg/kg/min, beyond which insulin secretion is expected and further increases may cause hyperglycaemia. A GIR persistently exceeding 10-12 mg/kg/min despite normal or elevated blood glucose, particularly in the presence of elevated insulin levels, is a strong diagnostic pointer to hyperinsulinism — either congenital hyperinsulinism (CHI, from mutations in KATP channel genes ABCC8/KCNJ11 or other hyperinsulinism genes) or transient neonatal hyperinsulinism from maternal diabetes or birth stress. Calculation requires knowing the dextrose concentration (g/dL or %) of the infusion solution, the infusion rate in mL/h, and the patient's weight in kg.
GIR (mg/kg/min) = (Dextrose concentration % x Infusion rate mL/h) / (6 x Weight kg); alternative form: GIR = (Dextrose g/dL x Rate mL/h x 1000) / (60 x Weight kg x 100)
- 1Identify the dextrose concentration of the IV fluid: expressed as a percentage (e.g., D10% = 10g dextrose per 100mL = 10 g/dL).
- 2Record the infusion rate in mL per hour.
- 3Record the patient's weight in kilograms.
- 4Apply the formula: GIR (mg/kg/min) = (Dextrose% x Rate mL/h) / (6 x Weight kg). The factor 6 derives from: converting g to mg (x1000), converting hours to minutes (/60), and per 100 mL for concentration (/100).
- 5Compare to target: neonatal target GIR is 4-8 mg/kg/min; premature infants may need up to 10-12 mg/kg/min; GIR above 10-12 mg/kg/min without hyperglycaemia raises suspicion for hyperinsulinism.
- 6Adjust infusion rate or dextrose concentration to achieve target GIR while monitoring blood glucose every 1-4 hours.
- 7When investigating hyperinsulinism, a critical blood sample (glucose, insulin, C-peptide, fatty acids, ammonia, lactate, cortisol, GH) should be collected at the time of hypoglycaemia to establish the biochemical diagnosis.
Typical D10% maintenance for 3.5 kg neonate is 15-20 mL/h to achieve 4-8 mg/kg/min
To achieve a GIR of 6 mg/kg/min with D10% for a 3.5 kg neonate: Rate = GIR x 6 x weight / dextrose% = 6 x 6 x 3.5 / 10 = 12.6 mL/h. Standard neonatal D10% maintenance runs at approximately 12-16 mL/h for a term neonate — not 60 mL/h. Always verify the GIR against body weight.
Within target for premature neonate
A GIR of 5.2 mg/kg/min is within the target range for a premature neonate. D12.5% is used in peripheral infusions (D10% is the maximum safe peripheral concentration) or central lines. The rate is low but appropriate for this very small infant.
Consider: at GIR >8-10 with persistent hypoglycaemia — critical sample for hyperinsulinism
If a neonate requires progressively increasing GIR (particularly above 8-12 mg/kg/min) to maintain blood glucose above 2.6-3.5 mmol/L, congenital hyperinsulinism must be suspected. A critical sample at the time of hypoglycaemia (insulin, C-peptide, fatty acids, ketones) is diagnostic. Diazoxide is the first-line treatment for most forms of CHI.
Set D10% at approximately 10 mL/h to achieve GIR of 6 mg/kg/min
Rearranging the GIR formula allows calculation of the required infusion rate for a given target GIR, dextrose concentration, and patient weight. This is the clinically practical reverse calculation used when prescribing IV glucose for neonates.
Mortgage lenders and loan officers use Glucose Infusion Rate to structure repayment schedules, compare fixed versus adjustable rate options, and calculate total borrowing costs for residential and commercial real estate transactions across different term lengths.
Personal finance advisors apply Glucose Infusion Rate when counseling clients on debt reduction strategies, comparing the mathematical benefit of accelerated payments against alternative investment returns to determine the optimal allocation of surplus cash flow.
Credit unions and community banks rely on Glucose Infusion Rate to generate accurate Truth in Lending disclosures, ensure regulatory compliance with TILA and RESPA requirements, and provide borrowers with standardized cost comparisons across competing loan products.
Corporate treasury departments use Glucose Infusion Rate to model the cost of revolving credit facilities, term loans, and commercial paper programs, optimizing the company's capital structure and minimizing weighted average cost of debt financing.
Zero or negative interest rate
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in glucose infusion rate calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Balloon payment at maturity
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in glucose infusion rate calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Variable rate mid-term adjustment
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in glucose infusion rate calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Focal congenital hyperinsulinism
Approximately 40% of diazoxide-unresponsive CHI cases are caused by focal pancreatic lesions rather than diffuse disease. Focal CHI can be curettively managed by targeted partial pancreatectomy guided by 18F-DOPA PET-CT, which identifies the metabolically active focal lesion. GIR monitoring is essential post-operatively to confirm resolution of hyperinsulinism.
| GIR (mg/kg/min) | Clinical Interpretation | Action |
|---|---|---|
| < 4 | Below hepatic glucose output — supplementation needed | Increase rate or concentration |
| 4 - 8 | Normal neonatal target range | Maintain; monitor glucose |
| 8 - 12 | High requirement — watch for hyperglycaemia | Monitor closely; exclude hyperinsulinism if glucose still low |
| > 12 with normoglycaemia | Hyperinsulinism very likely | Collect critical sample; start diazoxide if confirmed CHI |
| > 10-12 with persistent hypoglycaemia | Hyperinsulinism — urgent assessment | Critical sample; paediatric endocrinology referral |
Why is GIR expressed per kilogram per minute?
Glucose metabolism in neonates is closely related to body weight (and therefore metabolically active tissue mass). Expressing GIR per kg/min normalises for body size, allowing universal target ranges to be applied regardless of gestational age or birth weight — from a 500g extremely premature infant to a 5kg term neonate.
What dextrose concentrations can be given peripherally?
Peripheral IV lines tolerate dextrose concentrations up to approximately 12.5% (D12.5%). Higher concentrations (D15%, D20%, D25%) cause phlebitis and endothelial damage and must be given via central venous access (umbilical venous catheter, long line/PICC, or central venous line). D10% is the most commonly used peripheral concentration in neonatal intensive care.
What is the target blood glucose in neonates?
The operational threshold for treating neonatal hypoglycaemia is a blood glucose below 2.6 mmol/L (47 mg/dL) in most UK and international guidelines. Some guidelines use 2.2 mmol/L (40 mg/dL) for the first 4 hours of life in at-risk neonates. Target blood glucose on IV glucose therapy is typically 3.0-6.0 mmol/L (54-108 mg/dL). Hyperglycaemia (above 8-10 mmol/L) in neonates is associated with adverse outcomes and may require insulin infusion.
When should hyperinsulinism be suspected?
Hyperinsulinism should be suspected when: the GIR required to maintain blood glucose above 3.5 mmol/L exceeds 8-10 mg/kg/min; hypoglycaemia is severe (below 2.2 mmol/L); hypoglycaemia recurs despite increasing GIR; or hypoglycaemia is associated with suppressed ketones and fatty acids at the time of hypoglycaemia. A critical blood sample (insulin, C-peptide, fatty acids, ketones, ammonia, cortisol) during hypoglycaemia is essential for diagnosis.
What is the GIR target for neonates?
Glucose Infusion Rate is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
Can the GIR formula be used for adults?
GIR can be calculated for adults receiving parenteral nutrition or IV glucose supplementation using the same formula. However, adult glucose requirements per kg are much lower than neonatal requirements — typically 1-4 mg/kg/min. GIR above 4 mg/kg/min in adults may cause hyperglycaemia requiring insulin. The formula is most commonly applied in neonatal and paediatric intensive care.
What is the glucose-to-insulin ratio and how does it relate to GIR?
The glucose-to-insulin ratio (G:I ratio) is calculated by dividing blood glucose (mg/dL) by insulin (microU/mL) at the time of hypoglycaemia. A ratio below 2.6 strongly supports hyperinsulinism. The G:I ratio is used alongside the required GIR to confirm the diagnosis — hyperinsulinism is characterised by the combination of high GIR requirement to prevent hypoglycaemia and inappropriately elevated insulin at the time of hypoglycaemia.
What is diazoxide and when is it used for hyperinsulinism?
Glucose Infusion Rate is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
전문가 팁
To quickly check if a GIR is correct in your head: for D10%, the GIR in mg/kg/min approximately equals the infusion rate in mL/h divided by (0.6 x weight in kg). For example, D10% at 9 mL/h in a 2.5 kg infant: GIR ≈ 9 / (0.6 x 2.5) = 9/1.5 = 6 mg/kg/min. This mental shortcut works only for D10%.
알고 계셨나요?
The recognition that GIR above 10-12 mg/kg/min suggests hyperinsulinism arose from studies of normal neonatal hepatic glucose production, measured by isotope tracer techniques in the 1970s and 1980s. These studies established that the normal neonatal liver produces approximately 4-6 mg/kg/min of glucose — making any GIR requirement much above this figure an indicator of suppressed hepatic glucose output by excessive insulin.
참고 자료
- ›Thornton PS et al. Congenital Hyperinsulinism. Journal of Pediatrics 2015
- ›Stanley CA. Perspective on the genetics and diagnosis of congenital hyperinsulinism. J Clin Endocrinol Metab 2016
- ›NICE NG3 — Diabetes in Pregnancy: Management from Preconception to the Postnatal Period 2015
- ›British Association of Perinatal Medicine — Identification and Management of Neonatal Hypoglycaemia 2017